Prognostic role of maspin expression in patients with cervical dysplasia and cervical cancer.
cervical cancer
cervical intraepithelial neoplasia
maspin
survival
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
22
05
2019
accepted:
07
02
2020
pubmed:
23
2
2020
medline:
4
2
2021
entrez:
21
2
2020
Statut:
ppublish
Résumé
Mammary serine protease inhibitor (maspin) acts as a tumor suppressor through the inhibition of cancer cell invasion and metastasis. Paradoxically, maspin levels are increased in some types of malignant cells. The aim of this study was to investigate the maspin expression in cervical dysplasia and cervical cancer, and to analyze its' relation with survival. Maspin expression was detected by immunohistochemistry using labeled streptavidin biotin method to determine cytoplasmic and nuclear maspin expressions in cervical intraepithelial neoplasia grade 1 (CIN1), cervical intraepithelial neoplasia grade 2 (CIN2), cervical intraepithelial neoplasia grade 3 (CIN3) and cervical cancer. A total of 89 patients with CIN (29 cases of CIN1, 30 cases of CIN2 and 30 cases of CIN3), and 27 patients with cervical cancer were included to the study. 7.8% of the patients with CIN had maspin staining positivity. On the other hand maspin staining was positive in 20 of 27 patients (74.1%) with cervical carcinoma (P = 0.001). Of these patients 20 (100%) had cytoplasmic, and 8 (40%) had nuclear maspin staining positivity. Cytoplasmic maspin immunoreactive scores were found to be significantly higher in carcinoma group when compared to the patients with CIN1/3 (respectively; P = 0.01, P = 0.02). No difference was noted for nuclear maspin expression. Significant overall survival advantage was detected for patients with nuclear maspin staining (P = 0.03). The current study shows that nuclear maspin expression is related with better overall survival in cervical cancer. Maspin staining can be a useful diagnostic marker to discriminate cervical intraepithelial neoplasia from cervical carcinoma.
Substances chimiques
Biomarkers, Tumor
0
SERPIN-B5
0
Serpins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-764Informations de copyright
© 2020 Japan Society of Obstetrics and Gynecology.
Références
Ferlay J, Soerjomataram I, Ervik M, et al. International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.
Schneider SS, Schick C, Fish KE et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A 1995; 92: 3147-3151.
Zhang M, Maass N, Magit D, Sager R. Transactivation though Ets and Ap1 transcriptional sites determines the expression of the tumor-suppressing gene mason. Cell Growth Differ 1997; 8: 179-186.
Murai S, Maesawa C, Masuda T, Sugiyama T. Aberrant maspin expression in human endometrial cancer. Cancer Sci 2006; 97: 883-888.
Zou Z, Anisowicz A, Hendrix MJ et al. Maspin, a serpin with tumor- suppressing activity in human mammary epithelial cells. Science 1994; 263: 526-529.
Sood AK, Fletcher MS, Gruman LM et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8: 2924-2932.
Li HW, Leung SW, Chan CS, Yu MM, Wong YF. Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep 2007; 17: 393-398.
Xu C, Quddus MR, Sung CJ, Steinhoff MM, Zhang C, Lawrence WD. Maspin expression in CIN 3, microinvasive squamous cell carcinoma, and invasive squamous cell carcinoma of the uterine cervix. Mod Pathol 2005; 18: 1102-1106.
Wongnoppavich A, Dukaew N, Choonate S, Chairatvit K. Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non-Smad signaling pathways. Oncol Lett 2017; 13: 3646-3652.
Secord AA, Lee PS, Darcy KM et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 390-397.
Surowiak P, Materna V, Drag-Zalesinska M et al. Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 2006; 25: 131-139.
The Global Cancer Observatory. GLOBOCAN Cancer Fact Sheets: Cervical Cancer 2012. Lyon, France: The Global Cancer Observatory. Available from URL: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp
Zou Z, Gao C, Nagaich AK et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000; 275: 6051-6054.
Boltze C, Schneider-Stock R, Quednow C et al. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int J Mol Med 2003; 12: 479-484.
Yatabe Y, Mitsudomi T, Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: Cellular property-associated expression under the control of promoter DNA methylation. Oncogene 2004; 23: 4041-4049.
Friedrich MG, Toma MI, Petri S et al. Expression of maspin in non-muscle invasive bladder carcinoma: Correlation with tumor angiogenesis and prognosis. Eur Urol 2004; 45: 737-743.
Rose SL, Fitzgerald MP, White NO et al. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol 2006; 102: 319-324.
Nosaka K, Horie Y, Shiomi T et al. Cytoplasmic maspin expression correlates with poor prognosis of patients with adenocarcinoma of the uterine cervix. Yonago Acta Med 2015; 58: 151-156.
Torres A, Torres K, Paszkowski T et al. Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: A preliminary report. Int J Gynecol Cancer 2011; 21: 8-14.
Liu H, Shi J, Anandan V et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med 2012; 136: 601-609.
Taskiran C, Erdem O, Onan A et al. Maspin expression in endometrial hyperplasia and carcinoma, and its relation with angiogenesis. Eur J Gynaecol Oncol 2014; 35: 134-139.
Goulet B, Kennette W, Ablack A et al. Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest 2011; 91: 1181-1187.
Machowska M, Wachowicz K, Sopel M, Rzepecki R1. Nuclear location of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer 2014; 28: 142.
Umekita Y, Souda M, Yoshida H. Expression of maspin in colorectal cancer. In Vivo 2006; 13: 317-321.
Tsuji T, Togami S, Douchi T, Umekita Y. Difference in subcellular localization of maspin expression in ovarian mucinous borderline tumour. Histopathology 2009; 55: 130-132.
Takagi Y, Matsuoka Y, Shiomi T et al. Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring less than 3 cm. Histopathology 2015; 66: 732-739.
Takeda C, Takagi Y, Shiomi T et al. Cytoplasmic maspin expression predicts poor prognosis of patients with soft tissue sarcomas. Diagn Pathol 2014; 30: 205.
Solomon LA, Munkarah AR, Schimp VL et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 2006; 101: 385-389.